Drug Use-Results Survey of OPDIVO (malignant melanoma)

Not Applicable

• Conditions: Malignant melanoma

• Registration Number: JPRN-jRCT1080223217
• Lead Sponsor: ONO PHARMACEUTICAL CO., LTD.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-25
• Study Completion: 2021-09-07
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: other
• Sex: All
• Target Recruitment: 1700

Inclusion Criteria

All patients with unresectable malignant melanoma for whom OPDIVO is administered

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
safety<br>Safety items : Occurrence status of adverse events (including adverse drug reactions)

Secondary Outcome Measures

Name	Time	Method
efficacy<br>Efficacy items : Comprehensive improvement (the best antitumor efficacy by 6 and 12 months after the initiation of OPDIVO or by the end or discontinuation of the treatment)